Combined modality staging of prostate carcinoma and its utility in predicting pathologic stage and postoperative prostate specific antigen failure

Urology

Volumn 49, Issue 3 SUPPL., 1997, Pages 23-30

  D'Amico, Anthony V ^a,d   Whittington, Richard ^b   Malkowicz, S Bruce ^b   Schultz, Delray ^c   Schnall, Mitch ^b   Tomaszewski, John E ^b   Wein, Alan ^b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^c MILLERSVILLE UNIVERSITY   (United States)

^d HARVARD RADIATION ONCOLOGY PROGRAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ANTIGEN DETECTION; CANCER INVASION; CANCER STAGING; CONFERENCE PAPER; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS POTENTIAL; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CARCINOMA; RISK ASSESSMENT;

GENITAL NEOPLASMS, MALE; HUMANS; LOGISTIC MODELS; MAGNETIC RESONANCE IMAGING; MALE; MULTIVARIATE ANALYSIS; NEOPLASM INVASIVENESS; NEOPLASM STAGING; POSTOPERATIVE PERIOD; PREDICTIVE VALUE OF TESTS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RISK FACTORS; SEMINAL VESICLES;

EID: 0030944954     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(97)00165-9     Document Type: Conference Paper

References (24)

1. Epstein JI, Pizov G, and Walsh PC: Correlation of pathologic findings with progression after radical retropubic prostatectomy. Cancer 71: 3582-3589, 1993.
2. Forman JD, Wharman MD, and Lee DJ, et al: Definitive radiotherapy following prostatectomy: results and complications. Int J Radiat Oncol Biol Phys 12: 185-190, 1986.
3. Freeman JA, Lieskovsky G, and Cook DW, et al: Radical retropubic prostatectomy and postoperative adjuvant radiation for pathological stage C (PCNO) prostate cancer from 1976 to 1989: intermediate findings. J Urol 149: 1029-1036, 1993.
4. D'Amico AV, Whittington R, Malkowicz SB, Schnall M, Tomaszewski J, Schultz D, Kao G, Vanarsdalen K, and Wein A: A Multivariable analysis of clinical factors predicting for pathological features associated with local failure after radical prostatectomy for prostate cancer. Int J Radiat Oncol Biol Phys 30: 292-300, 1994.
5. Cox DR: Regression models and life tables. J R Stat Soc (Series B) 34: 1-99, 1972.
6. Partin AW, Yoo J, and H Ballentine Carter, et al: The use of prostate specific antigen, clinical stage, and gleason score to predict pathologic stage in men with prostate cancer. J Urol 150: 110-115,1993.
7. Presti JC, Katsuto S, Hricak H, White S, Cher M, and Carroll PR: Clinical parameters in the preoperative evaluation for extracapsular extension at radical prostatectomy (abst). 90th Annual Meeting of the American Urological Association, Las Vegas, NV; 429A, 1995.
8. Narayan P, Gajendran V, Taylor SP, Tewari A, Presti JC Jr, Leidich R, Lo R, Palmer K, Shinohara K, and Spaulding JT: The role of transrectal ultrasound-guided biopsy based staging, preoperative prostate specific antigen, and biopsy Gleason score in prediction of final pathologic diagnosis in prostate cancer. Urology 46: 205-212, 1995.
9. Myrtle JF, Klimley PG, Ivor LP, and Brun JF: Clinical utility of prostate-specific antigen (PSA) in the management of prostate cancer, in Advances in Cancer Diagnosis. Hybritech, Inc., 1986.
10. Beahrs OH, Henson DE, Hutter RVP, and Kennedy BJ: American Joint Committee on Cancer Manual for Staging Cancer, 4th ed. J.P. Lippincott, Philadelphia, 1992.
11. Schnall MD, Lenkinski RE, Pollack HM, Imai Y, and Kressel HY: Prostate: MR imaging with an endorectal surface coil. Radiology 172: 570-575, 1989.
12. Schiebler ML, Schnall M, Pollack HM, Lenkinski RE, Tomaszewski JE, Wein AJ, Whittington R, Rauschning W, and Kressel HY: Current role of MR imaging in the staging of adenocarcinoma of the prostate. Radiology 189: 339-351, 1993.
13. Kaplan EL, and Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53: 457-467, 1958.
14. Carter HB, and Coffey DS: Prostate cancer: the magnitude of the problem in the United States, in Coffey DS, Resnick MI, Dorr FA, and Karr JP (eds): A Multidisciplinary Analysis of Controversies in the Management of Prostate Cancer. New York, Plenum Press, 1988, pp 1-7.
15. Catalona WJ, and Dresner SM: Nerve-sparing radical prostatectomy: extraprostatic tumor extension and preservation of erectile function. J Urol 134: 1149-1152, 1985.
16. Eggleston JC, and Walsh PC: Radical prostatetomy with preservation of sexual function: pathologic findings in the radical prostatectomy specimens. Urology 134: 1146-1148, 1985.
17. Gibbons RP, Cole BS, and Richardson RG: Adjuvant radiotherapy following radical prostatectomy: results and complications. J Urol 135: 65-69, 1986.
18. Middleton RG, Smith JS Jr, Metzer RB, and Hamilton PE: Patient survival and local recurrence following radical prostatectomy for prostatic carcinoma. J Urol 136: 422-425, 1986.
19. Thompson I, Crawford ED, Miller G, Paradielo J, Blumenstein B, Wolfe M, Moinpour C, Hayden K, and Messing E: Adjuvant radiotherapy following radical prostatectomy for pathologic stage C adenocarcinoma of the prostate: initial evaluation of toxicity. J Clin Oncol, Abstract 212: 663, 1992.
20. Keetch DW, Catalona WJ, and Smith DS: Serial prostatic biopsies in men with persistently elevated serum prostate specific antigen values. J Urol 151: 1571-1574, 1994.
21. Katz AE, Olsson, CA, Raffo AJ, Cama C, Perlman H, Seaman E, O'Toole KM, McMahon D, Benson MC, and Buttyan R: Molecular staging of prostate cancer with the use of an enhanced reverse transcriptase-PCR assay. Urology 43: 765-776, 1994.
22. D'Amico, AV, Whittington R, Malkowicz SB, Schnall M, Tomaszewski JE, Schultz D, and Wein A: A multivariate analysis of clinical and pathological factors which predict for pros-tate-specific antigen failure after radical prostatectomy for prostate cancer. J Urol 154: 131-138, 1995.
23. Ravery V, Boccon-Gibod LA, Dauge-Geffroy MC, Billebaud T, Delmas V, Meulemans A, Toublanc M, and Boccon-Gibod L: Systematic biopsies accurately predict extracapsular extension of prostate cancer and persistent/recurrent detectable PSA after radical prostatectomy. Urology 44: 371-376, 1994.
24. Peller PA, Young DC, Marmaduke DP, Marsh W, and Badalament RA: Sextant prostate biopsies, a histopathologic correlation with radical prostatectomy specimens. Cancer 75: 530-537, 1995.